Skip to main content
Log in

Intramuscular Preparations of Antipsychotics

Uses and Relevance in Clinical Practice

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Intramuscular formulations of antipsychotics can be sub-divided into two groups on the basis of their pharmacokinetic features: short-acting preparations and long-acting or depot preparations. Short-acting intramuscular formulations are used to manage acute psychotic episodes. On the other hand, long-acting compounds, also called ‘depot’, are administered as antipsychotic maintenance treatment to ensure compliance and to eliminate bioavailability problems related to absorption and first pass metabolism.

Adverse effects of antipsychotics have been studied with particular respect to oral versus short- and long-acting intramuscular formulations of the different compounds. For short-term intramuscular preparations the main risk with classical compounds are hypotension and extrapyramidal side effects (EPS). Data on the incidence of EPS with depot formulations are controversial: some studies point out that the incidence of EPS is significantly higher in patients receiving depot preparations, whereas others show no difference between oral and depot antipsychotics.

Studies on the strategies for switching patients from oral to depot treatment suggest that this procedure is reasonably well tolerated, so that in clinical practice depot antipsychotic therapy is usually begun while the oral treatment is still being administered, with gradual tapering of the oral dose.

Efficacy, pharmacodynamics and clinical pharmacokinetics of haloperidol decanoate, fluphenazine enanthate and decanoate, clopenthixol decanoate, zuclopenthixol decanoate and acutard, flupenthixol decanoate, perphenazine enanthate, pipothiazine palmitate and undecylenate, and fluspirilene are reviewed. In addition, the intramuscular preparations of atypical antipsychotics and clinical uses are reviewed. Olanzapine and ziprasidone are available only as short-acting preparations, while risperidone is to date the only novel antipsychotic available as depot formulation.

To date, acutely ill, agitated psychotic patients have been treated with high parenteral doses of typical antipsychotics, which often cause serious EPS, especially dystonic reactions. Intramuscular formulations of novel antipsychotics (olanzapine and ziprasidone), which appear to have a better tolerability profile than typical compounds, showed an equivalent efficacy to parenteral typical agents in the acute treatment of psychoses. However, parenteral or depot formulations of atypical antipsychotics are not yet widely available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12(2): 135–50

    Article  Google Scholar 

  2. Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106–9

    Article  PubMed  CAS  Google Scholar 

  3. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int J Psychopharmacol 1995; 10: 207–13

    Article  CAS  Google Scholar 

  4. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321(7273): 1371–6

    Article  PubMed  CAS  Google Scholar 

  5. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9

    Article  PubMed  CAS  Google Scholar 

  6. Barnes TRE, Curson DA. Long-term depot antipsychotics a risk-benefit assessment. Drug Saf 1994; 10(6): 464–79

    Article  PubMed  CAS  Google Scholar 

  7. Ayd FJ. The depot fluphenazines: a reappraisal after 10 years clinical experience. Am J Psychiatry 1975; 132: 491–500

    PubMed  Google Scholar 

  8. Johnson DAW. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 1977; 17: 546–58

    PubMed  CAS  Google Scholar 

  9. Altamura AC, Tacchini GL, Maes M. Haloperidol plasma ‘Threshold’ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur Neuropsychopharmacol 1995; 5(S): 55–8

    Article  PubMed  CAS  Google Scholar 

  10. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7

    Article  PubMed  CAS  Google Scholar 

  11. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95: 464–8

    Article  PubMed  CAS  Google Scholar 

  12. Davis JM, Leor M, Watanabe MD, et al. Depot antipsychotic drugs, place in therapy. Drugs 1994; 47(5): 741–73

    Article  PubMed  CAS  Google Scholar 

  13. Altamura AC, Whelpton R, Curry SH. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Biopharm Drug Dispos 1979; 1: 65–72

    Article  PubMed  CAS  Google Scholar 

  14. Curry SH, Altamura AC, Montgomery S. Unwanted effects of fluphenazine enanthate and decanoate. Lancet 1979; I: 331–3

    Article  Google Scholar 

  15. Milton GV, Jann MW. Emergency treatment of psychotic symptoms: pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet 1995; 28(6): 494–504

    Article  PubMed  CAS  Google Scholar 

  16. Tune L. The role of antipsychotics in treating delirium. Curr Psychiatry Rep 2002; 4(3): 209–12

    Article  PubMed  Google Scholar 

  17. Altamura AC. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they ‘stabilizer’ rather than typical compounds? Int Clin Psychopharmacol 1996; 11: 1–3

    Article  Google Scholar 

  18. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001; 62 Suppl. 2: 22–4

    PubMed  CAS  Google Scholar 

  19. Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987; 16(3): 319–22

    Article  PubMed  CAS  Google Scholar 

  20. Schaffer CB, Shahid A, Javaid JI, et al. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 1982; 2: 274–7

    Article  PubMed  CAS  Google Scholar 

  21. Dubin WR, Wasman HM, Weiss KJ, et al. Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry 1985; 46: 475–8

    PubMed  CAS  Google Scholar 

  22. Hughes DH. Acute polypharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999; 50: 1135–7

    PubMed  CAS  Google Scholar 

  23. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989; 146: 1598–601

    PubMed  CAS  Google Scholar 

  24. Hyman SE. Acute psychoses and catatonia. In: Hyman SE, Tesar GE, editors. Manual of psychiatric emergencies. 3rd ed. Boston (MA): Little, Brown, 1994: 143–57

    Google Scholar 

  25. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001; 9(3): 89–104

    Article  PubMed  CAS  Google Scholar 

  26. Lazarus A, Dubin WR, Jaffe R. Rapid tranquilization with neuroleptic drugs. Clin Neuropharmacol 1989; 12: 303–11

    Article  PubMed  CAS  Google Scholar 

  27. Ericksen SE, Hurt SW, Chang S, et al. Haloperidol dose, plasma levels, and clinical response: a double blind study. Psychopharmacol Bull 1978; 14: 15–6

    PubMed  CAS  Google Scholar 

  28. Donlon PT, Meadow A, Tupin JP, et al. High versus standard dose of fluphenazine HCL in acute schizophrenia. J Clin Psychiatry 1978; 39: 800–4

    PubMed  CAS  Google Scholar 

  29. Escobar JI, Barron A, Kiriakos R. A controlled study of neuroleptisation with fluphenazine hydrochloride injections. J Clin Psychopharmacol 1983; 3: 359–62

    Article  PubMed  CAS  Google Scholar 

  30. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuro-psychopharmacol 1998; 8: 55–66

    Article  CAS  Google Scholar 

  31. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9: 17–20

    Article  PubMed  Google Scholar 

  32. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62(3): 153–7

    Article  PubMed  CAS  Google Scholar 

  33. Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6(5): 367–81

    Article  CAS  Google Scholar 

  34. Falloon I, Watt DC, Shepherd M. A comparative control trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8: 59–70

    Article  PubMed  CAS  Google Scholar 

  35. Quitkin F, Rifkin A, Kane JM, et al. Long-acting oral vs injectable antipsychotic drugs in schizophrenics. Arch Gen Psychiatry 1978; 35: 889–92

    Article  PubMed  CAS  Google Scholar 

  36. Weiden P, Rapkin B, Zygmut A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995; 46(10): 1049–54

    PubMed  CAS  Google Scholar 

  37. Curry SH. Metabolism and kinetics of chloropromazine in relation to effect. In: Sedvall G, Uvnas B, Zolterman R, editors. Antipsychotic drugs: pharmacokinetics and pharmacodynamics. Oxford: Pergamon Press, 1976: 343–52

    Google Scholar 

  38. Altamura AC. A multidimensional (pharmacokinetic and clinical-biological) approach to the neuroleptic response in schizophrenia. Schizophr Res 1992; 8: 187–98

    Article  Google Scholar 

  39. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982; 141: 171–7

    Article  PubMed  CAS  Google Scholar 

  40. Wilkinson D. The suicide rate in schizophrenia. Br J Psychiatry 1982; 140: 138–41

    Article  PubMed  CAS  Google Scholar 

  41. Altamura AC, Bassetti R, Bignotti S, et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60(1): 47–55

    Article  PubMed  CAS  Google Scholar 

  42. Schooler NR. Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In: Albert M, editor. Controversies in schizophrenia. New York: Guilford Press, 1985: 380

    Google Scholar 

  43. Soni SD, Sampath G, Shah A, et al. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand 1992; 85(5): 354–9

    Article  PubMed  CAS  Google Scholar 

  44. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medication in preventing schizophrenic recidivism. J Clin Psychiatry 1987; 48(3): 94–7

    PubMed  CAS  Google Scholar 

  45. Johnson DA. Oral versus depot medication in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291: 56–64

    Article  PubMed  CAS  Google Scholar 

  46. Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 65–71

    PubMed  Google Scholar 

  47. Altamura AC, Mauri M, Mantero M, et al. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 1987; 76: 702–6

    Article  PubMed  CAS  Google Scholar 

  48. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335–40

    Article  PubMed  CAS  Google Scholar 

  49. Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. Arch Gen Psychiatry 1981; 38: 195–9

    Article  PubMed  CAS  Google Scholar 

  50. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177–80

    PubMed  CAS  Google Scholar 

  51. Chien CP, Cole JO. Depot phenotiazine treatment in acute psychosis: a sequential comparative clinical study. Am J Psychiatry 1973; 130: 13–8

    PubMed  CAS  Google Scholar 

  52. Del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 1975; 16: 32–6

    PubMed  Google Scholar 

  53. Kesseler KA, Waletzky JP. Clinical use of the antipsychotics. Am J Psychiatry 1981; 138: 202–9

    Google Scholar 

  54. Gelenberg AJ, Doller JC, Schooler NR, et al. Acute extra-pyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Am J Psychiatry 1979; 136: 217–9

    PubMed  CAS  Google Scholar 

  55. Vasavan NP, Suranyi-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol 1986; 6(l): 30S–7S

    Article  Google Scholar 

  56. Burch EA, Ayd FJ. Depot pipotiazine 1970–1982: a review. J Clin Psychiatry 1983; 44: 242–7

    PubMed  CAS  Google Scholar 

  57. Pakes GE. Haloperidol: profile of side-effects. In: Johnson P, editor. Haloperidol decanoate and the treatment of chronic schizophrenia. New York: Adis Press, 1982: 58–63

    Google Scholar 

  58. Youssef HA. Haloperidol decanoate in place of multiple drug therapy in chronic schizophrenic patients. Acta Therapeutica 1983; 9: 215–25

    Google Scholar 

  59. Knudsen P, Hansen LB, Auken G, et al. Perphenazine decanoate vs perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl 1985; 322: 15–28

    Article  PubMed  CAS  Google Scholar 

  60. Bransgrove LL, Kelly MW. Movement disorders in patients treated with long-acting injectable antipsychotic drugs. Am J Hosp Pharm 1994 Apr 1; 51(7): 895–9

    PubMed  CAS  Google Scholar 

  61. Altamura AC, Curry SH, Montgomery S, et al. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentration in schizophrenic patients. Psychopharmacology (Berl) 1985; 87(1): 30–3

    Article  CAS  Google Scholar 

  62. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992 Dec; 53: 426–33

    PubMed  CAS  Google Scholar 

  63. Kaneko S, Edwards JG, Goldie A, et al. Effect of haloperidol decanoate on the cardiovascular system. Jpn J Psychiatry Neurol 1991; 45(1): 73–7

    PubMed  CAS  Google Scholar 

  64. Starmark JE, Forsman A, Wahlstrom J. Abscesses following prolonged intramuscular administration of perphenazine enanthate. Acta Psychiatr Scand 1980; 62: 154–7

    Article  PubMed  CAS  Google Scholar 

  65. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain: London, 1993

    Google Scholar 

  66. Beresford R, Ward A. Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychoses. Drugs 1987; 33: 31–49

    Article  PubMed  CAS  Google Scholar 

  67. Wei FC, Jann MW, Lin HN, et al. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry 1996; 57(7): 298–302

    PubMed  CAS  Google Scholar 

  68. Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 1993; 44(12): 1155–61

    PubMed  CAS  Google Scholar 

  69. Altamura AC, Colacurcio F, Mauri MC, et al. Haloperidol decanoate in chronic schizophrenia: a follow-up study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 163–70

    Article  PubMed  Google Scholar 

  70. Altamura AC, Vita A, Giobbio GM, et al. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol 1994; 9(1): 3–7

    Article  PubMed  Google Scholar 

  71. Kane JM, Davis JM, Schooler NR, et al. A one-year comparison of four dosages of haloperidol decanoate. Psychopharmacol Bull 1994; 30: 107, 1994

    Google Scholar 

  72. Zonda T, Kovari E. Use of haloperidol decanoate in psychiatric diseases. Ther Hung 1992; 40(2): 64–8

    PubMed  CAS  Google Scholar 

  73. Froemming JS, Lam YW, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17(6): 396–423

    Article  PubMed  CAS  Google Scholar 

  74. Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand 1980; 62(4): 356–63

    Article  CAS  Google Scholar 

  75. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159(4): 554–60

    Article  PubMed  Google Scholar 

  76. Gelders YG, Reyntijens AJ, Ash CW, et al. 12-month study of haloperidol decanoate in chronic schizophrenic patients. Int Pharmacopsychiatry 1982; 17(4): 247–54

    PubMed  CAS  Google Scholar 

  77. Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia: a long-term double-blind cross-over comparison. Acta Psychiatr Scand 1986; 74(3): 255–62

    Article  PubMed  CAS  Google Scholar 

  78. McKane JP, Robinson AD, Wiles DH, et al. Haloperidol decanoate vs fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 1987; 151: 333–6

    Article  PubMed  CAS  Google Scholar 

  79. Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clin Neuropharmacol 1991; 14 Suppl. 2: S16–21

    PubMed  Google Scholar 

  80. Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001717

  81. Brook S, Lucey JV, Gunn K. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933–41

    Article  PubMed  CAS  Google Scholar 

  82. Wright P, Birkett MA, David S, et al. Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51

    Article  PubMed  CAS  Google Scholar 

  83. Ulrich S, Neuhof S, Braun V, et al. Reduced haloperidol does not interfere with antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Int Clin Psychopharmacol 1999; 14: 219–28

    Article  PubMed  CAS  Google Scholar 

  84. Altamura AC, Bareggi SR. Comment on ‘Reduced haloperidol does not interfere with antipsychotic activity of haloperidol in the treatment of acute schizophrenia’. Int Clin Psychopharmacol2000; 15: 303–4

    Article  PubMed  CAS  Google Scholar 

  85. Bucci L, Fuchs M, Simeon J, et al. Depot fluphenazine in the treatment of psychosis in a community mental health clinic. Dis Nerv Syst 1970; 31: 28–31

    PubMed  Google Scholar 

  86. Caffey EM, Diamond LS, Frank TV, et al. Discontinuation or reduction of chemotherapy in chronic scizophrenics. J Chronic Dis 1964; 17: 347–58

    Article  PubMed  Google Scholar 

  87. Carpenter Jr WT, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999 Mar; 156(3): 412–8

    PubMed  Google Scholar 

  88. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 1987; 44: 518–21

    Article  PubMed  CAS  Google Scholar 

  89. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989 Aug; 9(4): 247–53

    Article  PubMed  CAS  Google Scholar 

  90. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112–7

    PubMed  CAS  Google Scholar 

  91. Ahlfors UG, Dencker SJ, Gravem A, et al. Clopenthixol decanoate and perphenazine enantathe in schizophrenic patients: a double-blind Nordic multicentre trial. Acta Psychiatr Scand Suppl 1980; 279: 77–91

    PubMed  CAS  Google Scholar 

  92. Martyns-Yellow IS. The decanoate of flupenthixol and clopenthixol in the treatment of chronic schizophrenia in-patients: implications for community psychiatry. West Afr J Med 1993; 12(2): 110–3

    Google Scholar 

  93. Borsetti G, Rocco P, Spilimbergo PG, et al. Long-term treatment of chronic schizophrenics with clopenthixol decanoate. Pharmatherapeutica 1984; 4(1): 53–6

    PubMed  CAS  Google Scholar 

  94. Carney MW. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate. Pharmatherapeutica 1984; 4(1): 57–63

    PubMed  CAS  Google Scholar 

  95. Aaes-Jorgensen T. Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 77–85

    Article  PubMed  CAS  Google Scholar 

  96. Sieberns S, Spechtmeyer H. cis (Z)-Clopenthixol decanoate: a new depot neuroleptic. Int Pharmacopsychiatry 1982; 17(3): 170–84

    PubMed  CAS  Google Scholar 

  97. Lambert PA, Chabannes JP. A new injectable delayed-action neuroleptic with sedative and antipsychotic action: cis-(Z)-clopenthixol decanoate: clinical trials. Encephale 1984; 10(2): 83–91

    PubMed  CAS  Google Scholar 

  98. Solgaard T, Kistrup K, Aaes-Jorgensen T, et al. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients: minimum effective dose and corresponding serum levels. Pharmacopsychiatry 1994 May; 27(3): 119–23

    Article  PubMed  CAS  Google Scholar 

  99. Kasi HA. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance of schizophrenia. Pharmatherapeutica 1986; 4(9): 555–60

    Google Scholar 

  100. Bttig D. Use of clopixol acutard 50 and 100mg (zuclopenthixol acetate) as a therapeutic drug in crisis at the Cery psychiatric hospital. Schweiz Arch Neurol Psychiatr 1988; 139(5): 35–47

    PubMed  CAS  Google Scholar 

  101. Lowert AC, Rasmussen EM, Holm R, et al. Acute psychotic disorders treated with 5% zuclopenthixol acetate in ‘Viscoleo’ (Cisordinol-Acutard), a global assessment of the clinical effect: an open multi-centre study. Pharmatherapeutica 1989; 5(6): 380–6

    PubMed  CAS  Google Scholar 

  102. Reynolds JEF. Anxiolytic sedatives, hypnotics and neuroleptics. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993: 364–623

    Google Scholar 

  103. Budde G. Efficacy and tolerability of flupenthixol decanoate in the treatment of depression and psychosomatic disorders: a multicenter trial in general practice. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(5): 677–89

    Article  PubMed  CAS  Google Scholar 

  104. Maragakis BP. A double-blind comparison of oral amitriptyline and low-dose intramuscular flupenthixol decanoate in depressive illness. Curr Med Res Opin 1990; 12(1): 51–7

    Article  PubMed  CAS  Google Scholar 

  105. Poldinger W, Sieberns S. Depression-inducing and antidepressive effects of neuroleptics: experiences with flupenthixol and flupenthixol decanoate. Neuropsychobiol 1983; 10(2–3): 131–6

    CAS  Google Scholar 

  106. Quraishi S, David A. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001470

  107. Pach J, Finkbeiner T, Glaser T, et al. Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month period. Fortschr Neurol Psychiatr 1998; 66(10): 442–9

    Article  PubMed  CAS  Google Scholar 

  108. Kong DS, Yeo SH. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1989; 5(6): 371–9

    PubMed  CAS  Google Scholar 

  109. Singh AN. Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation. J Int Med Res1984; 12(1): 17–22

    PubMed  CAS  Google Scholar 

  110. Knudsen P, Hansen LB, Larsen NE. Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications. Acta Psychiatr Scand Suppl 1985; 322: 11–4

    Article  PubMed  CAS  Google Scholar 

  111. Quraishi S, David A. Depot perphenazine decanoate and enanthate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001717

  112. Tuninger E, Levander S. Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 1996; 169(5): 618–21

    Article  PubMed  CAS  Google Scholar 

  113. Tegeler J, Floru L. A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene. Pharmakopsychiatr Neuropsychopharmakol 1979 Sep; 12(5): 357–65

    PubMed  CAS  Google Scholar 

  114. Dencker SJ, Gios I, Martensson E, et al. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berl) 1994 Feb; 114(1): 24–30

    Article  CAS  Google Scholar 

  115. Imlah NW, Murphy KP. Ten-year follow-up of schizophrenic patients on pipothiazine palmitate. Curr Med Res Opin 1985; 9(7): 449–53

    Article  PubMed  CAS  Google Scholar 

  116. Woggon B, Dick P, Fleischhauer HJ, et al. Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate: results of a multicenter double-blind trial. Int Pharmacopsychiatry 1977; 12(4): 193–209

    PubMed  CAS  Google Scholar 

  117. Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. J Clin Pharmacol 1978 Feb–Mar; 18(2–3): 148–54

    PubMed  CAS  Google Scholar 

  118. Leong OK, Wong KE, Tay WK, et al. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Med J 1989; 30(5): 436–40

    PubMed  CAS  Google Scholar 

  119. Bechelli LP, Navas-Filho F. Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. Encephale 1986; 12(3): 121–5

    PubMed  CAS  Google Scholar 

  120. Steinert J, Neder A, Erba E, et al. A comparative trial of depot pipothiazine. J Int Med Res 1986; 14(2): 72–7

    PubMed  CAS  Google Scholar 

  121. Quraishi S, David A. Depot pipothiazine palmitate and undeclynate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001720

  122. Chouinard G, Annable L, Steinberg S. A controlled clinical trial of fluspirilene, a long acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1986; 6: 21–6

    Article  PubMed  CAS  Google Scholar 

  123. Kanowski S, Paur R. Experience with fluspirilene in gerontopsychiatry. Pharmakopsychiatr Neuropsychopharmakol 1980 May; 13(3): 137–43

    PubMed  CAS  Google Scholar 

  124. Tanghe A. A retrospective evaluation of long-term fluspirilene (IMAP) treatment. Acta Psychiatr Belg 1976 May; 76(3): 480–90

    PubMed  CAS  Google Scholar 

  125. Soni SD. Fluspirilene in the treatment of non-hospitalized schizophrenic patients. Curr Med Res Opin 1977; 4(9): 645–9

    Article  PubMed  CAS  Google Scholar 

  126. Russel N, Landmark J, Merskey H, et al. A double blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Can J Psychiatry 1982; 27(7): 593–6

    Google Scholar 

  127. Quraishi S, David A. Depot fluspirilene for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001718

  128. Carpenter Jr WT, Zito JM, Vitrai J, et al. Hypothesis testing: is clozapine’s superior efficacy dependent on moderate D2 receptor occupancy? Biol Psychiatry 1998 Jan 15; 43(2): 79–83

    Article  PubMed  CAS  Google Scholar 

  129. Meehan K, Zhang F, David S, et al. A Double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21(4): 389–97

    Article  PubMed  CAS  Google Scholar 

  130. Wright P, Jewell H, Mitchell M, et al. A preliminary study of the safety, efficacy and pharmacokinetics of intramuscular olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophr Res 1999; 36: 318

    Google Scholar 

  131. Wright P, Kiesler G, Mitchell M, et al. Safety and efficacy of intramuscular olanzapine in patients with acute non organic psychosis [abstract]. Schizophr Res 1999; 36: 318

    Google Scholar 

  132. Eerdekens M, Rasmussen M, Vermeulen A, et al. Kinetics and safety of a novel risperidone depot formulation [abstract]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S135

    Google Scholar 

  133. Gefvert O, Nyberg S, Persson P, et al. Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia [abstract]. Biol Psychiatry 2001; 49 Suppl. 8: 117S

    Google Scholar 

  134. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; (7): 59–67

  135. Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-term safety of long-acting risperidone microspheres [abstract]. Schizophr Res 2002; 53 Suppl. 3: 174

    Google Scholar 

  136. Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr Res 2002; 53 Suppl. 3: 174–5

    Google Scholar 

  137. Miceli J, Wilner K, Folger C, et al. Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: population pharmacokinetic modelling [abstract]. Eur Neuropsychopharmacol 1998; 8: S215

    Article  Google Scholar 

  138. Brook S, Swift R, Harrigan EP. The tolerability and efficacy of intramuscular ziprasidone [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: 215

    Article  Google Scholar 

  139. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular ziprasidone 20mg is effective in reducing agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacol 2001; 155: 128–34

    Article  CAS  Google Scholar 

  140. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone 2mg versus 10mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12–8

    Article  PubMed  CAS  Google Scholar 

  141. Dernovsek MZ, Prevolnik Rupel V, Rebolj M, et al. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry 2001; 16(8): 474–82

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Carlo Altamura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlo Altamura, A., Sassella, F., Santini, A. et al. Intramuscular Preparations of Antipsychotics. Drugs 63, 493–512 (2003). https://doi.org/10.2165/00003495-200363050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363050-00004

Keywords

Navigation